Expression of PRAME and WT1 in Multiple Myeloma Patients during High Dose Chemotherapy and Auto-SCT
Andrey Misurin(National Medical Research Center for Hematology), Valeryi Savchenko(National Medical Research Center for Hematology), Е. Н. Паровичникова(National Research Center for Hematology Russian Academy of Medical Sciences), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Tatyana Vladimirovna Gaponova(National Medical Research Center for Hematology)
Cited by 3
Related Papers
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59